Serious adverse events measured by surgery or procedure‐related complications within 30 days ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · patients undergoing non‐cardiac surgery/invasive procedures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life, measured by CRQ (dyspnoea, fatigue, emotional function, and mastery subscales) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Macrolide showed no clear difference in number of participants experiencing one or more exacerbations… compared with tetracycline (low certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause mortality 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
Number of people experiencing one or more exacerbations, Drug resistance/microbial sensitivity (as reported by trialists), including emergence of atypical bacteria, Number of participants colonised with Pseudomonas aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Quinolone showed no clear difference in number of participants experiencing one or more exacerbations… compared with tetracycline (low certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Quinolone showed no clear difference in number of participants experiencing one or more exacerbations… compared with macrolide (low certainty).
1 finding from 1 review
Mean blood loss (mL) visual estimation · women in the third stage of labour
1 finding from 1 review
Severe PPH (≥ 1000 mL) · women in the third stage of labour
Intravenous/intramuscular ergot alkaloids may leads to lower estimated or measured blood loss of at least 1000 mL visual estimation compared with no uterotonic agents (low certainty).
1 finding from 1 review
Haemoglobin (g/dL) · women in the third stage of labour
1 finding from 1 review
Use of therapeutic uterotonics · women in the third stage of labour
Intravenous/intramuscular ergot alkaloids may leads to lower use of therapeutic uterotonics compared with no uterotonic agents (low certainty).
1 finding from 1 review